(Q38384113)

2 September 2017

title

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study (English)

1 reference

2 September 2017

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Cosimo Martino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Andrea Sartore-Bianchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Sara Lonardi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Vittorina Zagonel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Francesco Leone

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Fortunato Ciardiello

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Roberto Labianca

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Fotios Loupakis

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Silvio Marco Veronese

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Salvatore Siena

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Silvia Marsoni

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

9

Katia Bencardino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

23

Patrizia Racca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

7

Massimo Rugge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

24

Giuseppe Tonini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

30

Marcello Gambacorta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

25

Calogero Lauricella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Frédérique Penaullt-Llorca

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mauro Risio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Walter Grigioni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Johannes Noe

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Carmine Pinto

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Stefania Mosconi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Claudio Graiff

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giuseppe Aprile

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Barbara Frau

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Carlo Garufi

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mauro Truini

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giuseppe Viale

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

9 October 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1481-1491

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26449765%20AND%20SRC:MED&resulttype=core&format=json

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

HER2/neu testing in primary colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Expression of HER2 in colorectal cancer does not correlate with prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

The HER-2/neu oncogene in tumors of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.98

Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma

21 January 2018

1 reference

12 December 2020

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

1 reference

12 December 2020

Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

1 reference

12 December 2020

Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas

1 reference

12 December 2020

Significance of human epidermal growth factor receptor 2 expression in colorectal cancer

1 reference

12 December 2020

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

1 reference

12 December 2020

HER2: biology, detection, and clinical implications

1 reference

12 December 2020